> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 6 Observations in Cipla FDA-483
- URL: https://www.fdaweb.com/6-observations-in-cipla-fda-483-2/
- Published: 2024-06-27T12:00:00.000Z
- Updated: 2026-09-14T14:34:27.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5157263

FDA has released the form FDA-483 issued following a 6/10-6/21 inspection at the Cipla drug manufacturing facility in Goa, India. The [observations](https://www.fda.gov/media/179606/download?ref=fdaweb.com) were:

- failure to establish and document the accuracy, sensitivity, specificity, and reproducibility of test methods;
- aseptic processing areas are deficient regarding the system for monitoring environmental conditions;
- aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions;
- failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has already been distributed;
- failure to exercise appropriate controls over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel; and
- failure to fully follow the responsibilities and procedures applicable to the quality control unit.